Pentamidine (dimesylate)

Pentamidine (MP-601205) dimesylate is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine dimesylate inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine dimesylate is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine dimesylate has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities[1][2][3][4].

Product Specifications

CAS Number

[6823-79-6]

Product Name Alternative

MP-601205 (dimesylate)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Fungal; Parasite; Phosphatase

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/pentamidine-dimesylate.html

Solubility

10 mM in DMSO

Smiles

N=C(N)C1=CC=C(C=C1)OCCCCCOC2=CC=C(C=C2)C(N)=N.OS(=O)(C)=O.OS(=O)(C)=O

Molecular Formula

C21H32N4O8S2

Molecular Weight

532.63

References & Citations

[1]Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1 (14) :1255-64.|[2]Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2 (10) : p. 1387-400.|[3]Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7 (5) :625-34.|[4]David C. Bean, et al. Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections? J Lab Precis Med 2017;2:49.